CIMT Annual Meeting 2025: Highly Immunodeficient NKG Mouse Models for Cancer Research
Date: May 12, 2025
Cyagen is proud to attend the Association for Cancer Immunotherapy (CIMT) 22nd Annual Meeting from May 12-24, 2025 in Mainz, Germany. Visit us at Booth #13 to discover how our severely immunodeficient NKG mouse models offer an immediate advantage for your research in oncology, immunotherapy, and beyond.
Our team will be available to discuss how Cyagen's highly immunodeficient NKG Mice (T/B/NK-null) and CRO platforms can support and accelerate your therapeutic antibody drug discovery. Ask us how you can try our NKG mice for free!
22nd CIMT Annual Meeting: Europe's Cancer Immunotherapy Meeting
- Cyagen Booth: 13
- Dates: May 12-14, 2025
- Location: Rheingoldhalle Congress Center | Mainz, Germany
Featured Cyagen Representatives
- Reza Rezaei, DVM, PhD, MBA (Vice President, Sales and Business Development)
- Alfred Akateh (Senior Sales and Business Development Manager, Europe)
huHSC-NKG-ProF Mouse Model: A New Tool for Advancing Tumor Immunology Research
Our team at Europe's Cancer Immunotherapy Meeting will be presenting our huHSC-NKG-ProF Mouse Model research poster displayed at our booth (#13). We welcome people to stop by and discuss our data, which presents the following conclusions:
- huHSC-NKG-Prof mice can exhibit high levels of human immune cells.
- A richer variety of human immune cell subtypes, such as MDSCs, Tregs. DCs, macrophages, and granulocytes, can be detected in huHSC-NKG-ProF mice.
- huHSC-NKG-Prof mice are a reliable tool for preclinical pharmacodynamic studies of tumor immunotherapy, showing particularly good performance in the research of tumor vaccines and ADCC mechanisms
If you would like to review the complete poster & research data, you may request the file to be sent via email here.
Free NKG Mouse Trial Program Details
You are invited to enjoy complimentary evaluation of Cyagen's severely immunodeficient NKG mice! Our NKG mice are generated by deleting the Il2rg gene from NOD-Scid genetic background mice and currently recognized as one of the models with the highest degree of immunodeficiency.
Act Fast — Limited Slots Available!
Applications are reviewed on a rolling basis, and demand is high. Don't miss your chance to maximize your research potential with Cyagen's NKG mice!
BOOK YOUR MEETING AT CIMT 2025
Request a meeting in-person at CIMT 2025 to discuss your project:
Request a Free Project Consultation
If you are interested in scheduling a free consultation on your CAM/CGT projects outside of the event, please Contact Us.
About Cyagen
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive collaborations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.
